×
About 2,503 results

AllMedicine Apolipoprotein A-I Center

Research & Reviews  1,237 results

Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Car...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490983
Circulation Khera AV, Demler OV et. al.

Apr 29th, 2017 - Recent failures of drugs that raised high-density lipoprotein (HDL) cholesterol levels to reduce cardiovascular events in clinical trials have led to increased interest in alternative indices of HDL quality, such as cholesterol efflux capacity, an...

Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipid...
https://doi.org/10.1016/j.jacc.2015.09.013
Journal of the American College of Cardiology; Nicholls SJ, Ruotolo G et. al.

Nov 13th, 2015 - Potent cholesteryl ester transfer protein (CETP) inhibitors have been shown to substantially increase high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I levels as monotherapy and combined with statins. However, data on the effects...

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807967
Circulation Mora S, Glynn RJ et. al.

Sep 4th, 2013 - Chemically measured high-density lipoprotein cholesterol (HDL-C) may not be the best clinical measure of HDL. Little is known about alternative HDL measures such as HDL size or particle number (HDL-P) as determinants of residual risk after potent ...

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of car...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807966
Circulation Boekholdt SM, Arsenault BJ et. al.

Aug 23rd, 2013 - It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on s...

A form of apolipoprotein a-I is found specifically in relapses of focal segmental glome...
https://doi.org/10.1111/j.1600-6143.2012.04338.x
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons; Lopez-Hellin J, Cantarell C et. al.

Dec 4th, 2012 - Recurrence of idiopathic focal segmental glomerulosclerosis (FSGS) following kidney transplantation occurs in a large percentage of patients. Accurate prediction of recurrence and elucidation of its pathogenesis are major therapeutic goals. To det...

see more →

Clinicaltrials.gov  1,253 results

Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Car...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490983
Circulation Khera AV, Demler OV et. al.

Apr 29th, 2017 - Recent failures of drugs that raised high-density lipoprotein (HDL) cholesterol levels to reduce cardiovascular events in clinical trials have led to increased interest in alternative indices of HDL quality, such as cholesterol efflux capacity, an...

Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipid...
https://doi.org/10.1016/j.jacc.2015.09.013
Journal of the American College of Cardiology; Nicholls SJ, Ruotolo G et. al.

Nov 13th, 2015 - Potent cholesteryl ester transfer protein (CETP) inhibitors have been shown to substantially increase high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I levels as monotherapy and combined with statins. However, data on the effects...

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807967
Circulation Mora S, Glynn RJ et. al.

Sep 4th, 2013 - Chemically measured high-density lipoprotein cholesterol (HDL-C) may not be the best clinical measure of HDL. Little is known about alternative HDL measures such as HDL size or particle number (HDL-P) as determinants of residual risk after potent ...

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of car...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807966
Circulation Boekholdt SM, Arsenault BJ et. al.

Aug 23rd, 2013 - It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on s...

A form of apolipoprotein a-I is found specifically in relapses of focal segmental glome...
https://doi.org/10.1111/j.1600-6143.2012.04338.x
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons; Lopez-Hellin J, Cantarell C et. al.

Dec 4th, 2012 - Recurrence of idiopathic focal segmental glomerulosclerosis (FSGS) following kidney transplantation occurs in a large percentage of patients. Accurate prediction of recurrence and elucidation of its pathogenesis are major therapeutic goals. To det...

see more →

News  13 results

ApoA-I Therapies Flop for Plaque Reduction
https://www.medpagetoday.com/cardiology/atherosclerosis/74221

Jul 25th, 2018 - Action Points Two studies of recombinant apolipoprotein A-I (the major HDL apolipoprotein) products failed to show an effect on coronary plaque volume assessed by intravascular ultrasound (IVUS). Note that based on these studies, the development o...

First Oral ApoA-I Booster Shows Mixed Results
https://www.mdedge.com/endocrinology/article/54195/obesity/first-oral-apoa-i-booster-shows-mixed-results
Bruce Jancin

Apr 1st, 2011 - CHICAGO – A novel oral drug designed to increase apolipoprotein A-I synthesis and thereby enhance HDL functionality showed mixed results in its first major clinical trial. The 299-patient, 12-week, randomized, double-blind ApoA-I Synthesis Stimula.

Infusion of Milano Apoprotein Causes Rapid Regression of Atherosclerosis
https://www.medscape.com/viewarticle/463893

Nov 3rd, 2003 - Nov. 4, 2003 — Infusion of the Milano apoprotein A rapidly causes regression of atherosclerosis in patients with acute coronary syndromes (ACS), according to the results of a preliminary randomized trial published in the Nov. 5 issue of The Journa...

Tangier Disease: Epidemiology, Pathophysiology, and Management
https://www.medscape.com/viewarticle/770608

Abstract and Introduction Abstract Tangier disease is one of the most severe forms of familial high-density lipoprotein (HDL) deficiency. Since its discovery it has been diagnosed in about 100 patients and is characterized by severe plasma deficie...

Cholesterol Efflux Capacity and Pre-beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib
https://www.medscape.com/viewarticle/854630

Abstract and Introduction Abstract Background Potent cholesteryl ester transfer protein (CETP) inhibitors have been shown to substantially increase high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I levels as monotherapy and combi...

see more →